GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laurus Labs Ltd (BOM:540222) » Definitions » EV-to-FCF

Laurus Labs (BOM:540222) EV-to-FCF : (As of Apr. 09, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Laurus Labs EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Laurus Labs's Enterprise Value is ₹331,289 Mil. Laurus Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was ₹0 Mil. Therefore, Laurus Labs's EV-to-FCF for today is .

The historical rank and industry rank for Laurus Labs's EV-to-FCF or its related term are showing as below:

BOM:540222' s EV-to-FCF Range Over the Past 10 Years
Min: -2672.32   Med: 0   Max: 0
Current: -2672.32

BOM:540222's EV-to-FCF is ranked worse than
100% of 548 companies
in the Drug Manufacturers industry
Industry Median: 24.07 vs BOM:540222: -2672.32

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-09), Laurus Labs's stock price is ₹579.20. Laurus Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹3.710. Therefore, Laurus Labs's PE Ratio (TTM) for today is 156.12.


Laurus Labs EV-to-FCF Historical Data

The historical data trend for Laurus Labs's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laurus Labs EV-to-FCF Chart

Laurus Labs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.15 471.72 975.36 4,749.47 -1,866.65

Laurus Labs Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1,866.65 - - -

Competitive Comparison of Laurus Labs's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laurus Labs's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Laurus Labs's EV-to-FCF falls into.


;
;

Laurus Labs EV-to-FCF Calculation

Laurus Labs's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=331288.653/0
=

Laurus Labs's current Enterprise Value is ₹331,289 Mil.
Laurus Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laurus Labs  (BOM:540222) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Laurus Labs's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=579.20/3.710
=156.12

Laurus Labs's share price for today is ₹579.20.
Laurus Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3.710.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Laurus Labs EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Laurus Labs's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Laurus Labs Business Description

Traded in Other Exchanges
Address
Road No. 7, Banjara Hills, 2nd Floor, Serene Chambers, Hyderabad, TG, IND, 500034
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.

Laurus Labs Headlines

No Headlines